Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02133703 · ClinicalTrials.gov registry record · NA

Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility

A NA study, sponsored by Georgetown University.

Completed
Registry status
NA
Development phase
369
Enrollment target

NCT02133703: Completed NA study, sponsored by Georgetown University.

NCT02133703 is a NA study that has completed, run by Georgetown University. The registered enrollment target is 369 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02133703, a NA study, has completed, sponsored by Georgetown University.

COMPLETED
Registry status
NA
Development phase
369 participants
Enrollment target

Study Summary

This non-therapeutic trial is for women who have received results of genetic testing for BRCA1/2 mutations. The trial compares decision support tools designed to facilitate informed decision making regarding risk management following testing to usual care. The researchers will test separate decision support tools for women who receive positive test results and women who receive negative/inconclusive test results. Among women who receive a positive test result, an interactive decision support intervention will be compared to a print intervention. Among women who receive an inconclusive result, an interactive intervention will be compared to usual care.

Primary Outcome

Knowledge of risk management options.

Interventions

  • BEHAVIORAL Enhanced Internet DA
  • BEHAVIORAL Internet DA
  • BEHAVIORAL Enhanced Print DA
  • BEHAVIORAL Print DA
  • BEHAVIORAL Inconclusive Results DA

Trial Details

FieldValue
Enrollment Target 369 participants
Start Date 2015-10
Est. Completion 2022-07-01
Phase NA
Georgetown University

227 total trials

What the finished NCT02133703 record still lists

NCT02133703 is an interventional study that assigns participants to a tested intervention. The registered 369 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).

The record links to 0 conditions, and to 5 interventions - of which Enhanced Internet DA is the first listed.

NCT02133703 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02133703 about?

NCT02133703 is a clinical study titled "Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility". This non-therapeutic trial is for women who have received results of genetic testing for BRCA1/2 mutations. The trial compares decision support tools designed to facilitate informed decision making regarding risk management following testing to usual care. The researchers will test separate decision...

What is the current status of trial NCT02133703?

This trial is currently completed. It is a NA study. The enrollment target is 369 participants. The study started on 2015-10. Estimated completion is 2022-07-01.

What interventions are being tested in trial NCT02133703?

The interventions under investigation include: Enhanced Internet DA (BEHAVIORAL), Internet DA (BEHAVIORAL), Enhanced Print DA (BEHAVIORAL), Print DA (BEHAVIORAL), Inconclusive Results DA (BEHAVIORAL).

Who is sponsoring clinical trial NCT02133703?

This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02133703's enrollment target sits among peer trials

369 281st of 2000 higher than 1,718 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06114836 · 369 participants · NA

    GERD Infant Feeding Therapeutics Trial (GIFT Trial)

  • NCT06585410 · 369 participants · Phase 3

    Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

  • NCT07256717 · 369 participants · NA

    BPIT 5-Week Multi-Site Study: Movement Efficiency, Mobility & Neuromuscular Adaptation

  • NCT02332668 · 370 participants · Phase 1

    A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02133703, the US trial registry maintained by the National Library of Medicine. NCT02133703 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.